ClinicalTrials.gov Registration and Results Reporting for Medical Device Trials
Comprehensive guide to medical device clinical trial registration and results reporting: 42 CFR Part 11 ADCT criteria, 21-day clocks, Form FDA 3674, 2026 CMP updates, and EU MDR Article 77.
In medical device clinical development, trial registration and results reporting are frequently treated as post-hoc administrative checkboxes. Regulatory and clinical operations teams often delegate ClinicalTrials.gov data entry to junior coordinators or academic investigators, assuming that public disclosure rules mirror pharmaceutical trials or carry minimal commercial consequence.
That assumption is dangerous. For medical device sponsors, public clinical trial registration and results disclosure are legally binding statutory obligations governed by Section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA 801), codified in 42 CFR Part 11, and interwoven with marketing authorization gatekeepers.
Failing to register an applicable device trial or submit results on time does not merely expose sponsors to potential civil money penalties of $15,107 per day; it directly jeopardizes commercial product launches. Under federal law, every 510(k) premarket notification, Premarket Approval (PMA), and Humanitarian Device Exemption (HDE) submission must include Form FDA 3674, certifying that all applicable trial registration and results submission requirements have been satisfied. A false, incomplete, or missing certification is a prohibited act under Section 301(jj) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and provides statutory grounds for FDA Refusal to Accept (RTA) or Refusal to File (RTF).
Furthermore, multinational device trials face an increasingly complex dual-disclosure landscape. While U.S. sponsors navigate the Protocol Registration and Results System (PRS), device investigations conducted in the European Union under EU MDR (Regulation (EU) 2017/745) Article 62 must satisfy the stringent end-of-study notification, Clinical Investigation Report (CIR), and layperson summary publication mandates of MDR Article 77 (and IVDR Article 73 for diagnostics). Because the European Clinical Trial Information System (CTIS) under Regulation (EU) No 536/2014 is restricted exclusively to medicinal products, and the EUDAMED Clinical Investigation and Performance Studies module remains under development, device teams must manage fragmented national submission channels alongside U.S. federal registers.
Disambiguation Note: This guide covers statutory and regulatory trial registration, delayed posting, results submission, and end-of-study disclosure requirements for medical devices and IVDs under 42 CFR Part 11, FDAAA 801, Form FDA 3674, EU MDR Article 77, and IVDR Article 73. It does not cover in-trial safety reporting clocks under 21 CFR 812.150 / MDR Article 80 (covered in our Device Trial Safety Reporting Guide), general clinical investigation plan design under ISO 14155:2026, or registry macro-landscape statistics (analyzed in our ClinicalTrials.gov Database Analysis).
Direct Answer to Core Scenario: If your team is running a pivotal trial for an unapproved implantable device under a U.S. IDE with trial sites in Germany and Italy under MDR Article 62, the study enrolled its first patient 5 weeks ago, and nothing is registered yet:
- U.S. Registration Status & Violation: The trial is legally an Applicable Device Clinical Trial (ADCT) under 42 CFR 11.22(b)(1)(ii) because it is interventional, non-feasibility, studies an FDA-regulated device, and operates under an FDA IDE number. Under 42 CFR 11.24(a), registration was due no later than 21 calendar days after enrolling the first subject. Because 5 weeks have elapsed, the trial is out of compliance. The sponsor must register immediately through the Protocol Registration and Results System (PRS).
- Unapproved Device Delayed Posting: Under 42 CFR 11.35(b)(2), because the device has never been previously approved or cleared, NIH will not publicly post the registration record until FDA approves or clears the device (or within 30 days post-approval), unless the sponsor elects earlier public posting. Note: If you plan to publish trial results in an ICMJE-member journal, ICMJE policy requires public registration at or before the time of first patient consent for enrollment; keeping the registration hidden in the CT.gov "device lock-box" does not satisfy that policy unless you affirmatively check the box electing early public posting.
- Results Due Date & Certificate of Delay: Standard results are due 1 calendar year after the Primary Completion Date (PCD) under 42 CFR 11.44(a). However, because the device was not approved or cleared for any use before the PCD, the sponsor may submit a Certificate of Delay under 42 CFR 11.44(c) before the 1-year deadline. This extends the results deadline to 30 calendar days after the earlier of FDA approval or clearance of the device for any studied use, or withdrawal of the marketing application without resubmission for at least 210 days — subject to an absolute statutory ceiling of 2 years from the certification date.
- The Gatekeeper (Form FDA 3674): When you submit the PMA, you must attach Form FDA 3674 certifying compliance with 42 CFR Part 11 and listing all relevant NCT numbers. Submitting a false certification or failing to register is a prohibited act under Section 301(jj) that halts PMA review.
- EU MDR Article 77 Obligations: In Europe, the trial cannot wait for marketing approval to disclose completion. You must notify each concerned Member State within 15 calendar days of the end of the clinical investigation (or within 24 hours if halted for safety reasons). You must submit the full Clinical Investigation Report (CIR) and a validated layperson summary within 1 year of study completion (or 3 months if terminated early). Because CTIS excludes device trials and the EUDAMED CI module is still in development, submissions currently run through national competent authority portals.
Which Device Trials Are Applicable Device Clinical Trials (ADCTs)?
Not every clinical study involving a medical device is legally required to register on ClinicalTrials.gov. The statutory registration and results reporting mandate applies specifically to Applicable Device Clinical Trials (ADCTs) as defined in Section 402(j)(1)(A)(ii) of the Public Health Service Act (PHS Act) and codified in 42 CFR 11.10(a) and 42 CFR 11.22(b)(1)(ii).
For clinical trials initiated on or after January 18, 2017 (the effective date of the 42 CFR Part 11 Final Rule), a device study is an ADCT if and only if it meets a four-part operational test:
+----------------------------------------------------------------------------------------------------+
| 42 CFR 11.22(b)(1)(ii) APPLICABLE DEVICE CLINICAL TRIAL (ADCT) TEST |
+----------------------------------------------------------------------------------------------------+
| |
| [ CRITERION 1: STUDY TYPE ] |
| Is the study INTERVENTIONAL? |
| (Prospective assignment of human subjects to one or more health-related device interventions) |
| | |
| YES |
| v |
| [ CRITERION 2: PRIMARY PURPOSE ] |
| Is the primary purpose OTHER THAN FEASIBILITY? |
| (Pivotal, prospective safety/effectiveness, postmarket confirmatory vs. early feasibility / EFS) |
| | |
| YES |
| v |
| [ CRITERION 3: REGULATORY JURISDICTION ] |
| Does the study evaluate a device product SUBJECT TO SECTION 510(k), 515, OR 520(m) of FD&C Act? |
| (Class II 510(k), Class III PMA, or Humanitarian Device Exemption / HDE) |
| | |
| YES |
| v |
| [ CRITERION 4: U.S. REGULATORY / GEOGRAPHIC ANCHOR (At least ONE required) ] |
| [A] At least one study facility is located in the United States or a U.S. territory; OR |
| [B] The device product is manufactured in and exported from the U.S. for clinical study; OR |
| [C] The study is conducted under an FDA INVESTIGATIONAL DEVICE EXEMPTION (IDE) NUMBER. |
| | |
| YES (To Any) |
| v |
| ================================================================================================ |
| RESULT: APPLICABLE DEVICE CLINICAL TRIAL (ADCT) |
| Mandatory 21-day registration (11.24) & 1-year results submission (11.44) apply under Part 11 |
| ================================================================================================ |
| |
+----------------------------------------------------------------------------------------------------+
The Four Operational Criteria Detailed
- Interventional Study Design (11.22(b)(1)(ii)(A)): The study must prospectively assign human participants to one or more interventions (which may include device interventions, sham procedures, or active controls) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. Observational registries and retrospective chart reviews are not interventional and are excluded from the mandatory ADCT definition.
- Primary Purpose Other Than Feasibility (11.22(b)(1)(ii)(B)): The statute explicitly carves out small feasibility studies and prototype evaluations. Under 42 CFR 11.10(a), a clinical trial designed primarily to test product feasibility, refine device design, or evaluate initial surgical handling (such as an FDA Early Feasibility Study (EFS) or first-in-human pilot involving fewer than 10 to 15 patients) is not an ADCT. However, once a trial evaluates safety and effectiveness endpoints intended to support a marketing submission (e.g., traditional feasibility, pivotal, or bridging studies), it meets this criterion.
- FDA-Regulated Device Product (11.22(b)(1)(ii)(C)): The trial must study a medical device product subject to Section 510(k) (premarket notification), Section 515 (PMA), or Section 520(m) (HDE) of the FD&C Act. This encompasses Class II devices subject to premarket notification, Class III devices requiring PMA, and humanitarian use devices, and it extends to combination products where the primary mode of action (PMOA) is device-led (42 CFR 11.10(a)).
- The U.S. Nexus Trigger (11.22(b)(1)(ii)(D)): The trial must satisfy at least one of three jurisdictional prongs:
- Facility Location: At least one investigational site is located in the U.S. or a U.S. territory.
- U.S. Export: The device is manufactured in the U.S. or a territory and exported under Section 801(e) or 802 of the FD&C Act for use in a foreign clinical investigation.
- FDA IDE Number: The clinical trial is conducted under an FDA Investigational Device Exemption (IDE) under 21 CFR Part 812.
Critical Strategic Insight: Many multinational sponsors mistakenly assume that if a clinical trial is conducted entirely at European or Asian investigative sites with zero U.S. patients, U.S. registration rules do not apply. This is false if the study operates under a U.S. IDE or tests a U.S.-manufactured export device. The presence of an FDA IDE number or U.S. device export is an independent statutory trigger under 42 CFR 11.22(b)(1)(ii)(D)(3) that renders the entire foreign study an Applicable Device Clinical Trial subject to full 42 CFR Part 11 registration and results disclosure.
Special Device Trial Categories
- Section 522 Postmarket Surveillance Studies: Under 42 CFR 11.10(a) and 42 CFR 11.22(b)(1)(i), any pediatric postmarket surveillance study of a device ordered by the FDA under Section 522 of the FD&C Act (21 CFR Part 822) is deemed an ADCT by statutory definition, regardless of whether it would otherwise be classified as an observational cohort or registry.
- Non-Significant Risk (NSR) Device Studies: An NSR device trial conducted under abbreviated IDE requirements (21 CFR 812.2(b)) that evaluates health outcomes against a control, has a non-feasibility purpose, and operates at a U.S. site is an ADCT and must be registered, even though no formal IDE application was submitted to FDA headquarters.
When Must a Device Trial Be Registered, and Who Is the Responsible Party?
The 21-Day Registration Clock
Under 42 CFR 11.24(a), the Responsible Party must submit complete clinical trial registration information to the Protocol Registration and Results System (PRS) not later than 21 calendar days after enrolling the first human subject.
+----------------------------------------------------------------------------------------------------+
| 42 CFR PART 11 CORE REGISTRATION & RESULTS TIMELINE |
+----------------------------------------------------------------------------------------------------+
| |
| [ DAY 0 ] |
| First Human Subject Enrolled (Signed Informed Consent & Meets Inclusion Criteria) |
| | |
| v <--- 21 Calendar Days (42 CFR 11.24(a)) |
| [ DAY 21 ] |
| MANDATORY REGISTRATION DEADLINE in ClinicalTrials.gov PRS |
| | |
| | [ If Unapproved/Uncleared Device (11.35(b)) ] ---> NIH Holds in "Device Lock-Box" |
| | [ If RP Elects Early Posting or Approved ] ---> NIH Posts Publicly within 30 Days |
| | |
| v <--- Trial Conduct, Follow-Up, Last Subject Evaluation |
| [ PRIMARY COMPLETION DATE (PCD) ] (42 CFR 11.10(a)) |
| Final Subject Examined / Intervened for Final Data Collection on Primary Outcome Measure |
| | |
| v <--- 1 Calendar Year (42 CFR 11.44(a)) |
| [ 1 YEAR POST-PCD ] |
| MANDATORY RESULTS SUBMISSION DEADLINE (Summary Data, Participant Flow, Adverse Events, SAP/PDF) |
| | |
| +--- [ OPTION A: STANDARD SUBMISSION ] ---> NIH Posts Publicly within 30 Days (11.52) |
| | |
| +--- [ OPTION B: CERTIFICATE OF DELAY (11.44(b)/(c)) ] Filed Prior to 1-Year Deadline |
| Extends Deadline to 30 Days After the Delay-Triggering Event (Hard 2-Year Cap) |
| |
+----------------------------------------------------------------------------------------------------+
The enrollment date that starts the 21-day clock is the date the first subject signs the informed consent document and is enrolled under the trial protocol. Registering on day 22 is a violation of 42 CFR 11.24(a).
Identifying the "Responsible Party" (RP)
Under 42 CFR 11.10(a) and 42 CFR 11.4, the Responsible Party bears full legal liability for Part 11 compliance. The RP is determined by a strict statutory hierarchy:
- The Sponsor (Default): The commercial entity, institution, or individual that initiates the clinical investigation and holds the IDE (or submits the 510(k)/PMA).
- The Designated Principal Investigator (PI): The sponsor may formally designate the trial PI as the Responsible Party only if all of the following conditions are met:
- The PI is responsible for conducting the trial;
- The PI has full access to and control over all clinical trial data;
- The PI has the unrestricted right to publish the trial results; and
- The PI possesses the organizational capacity to meet all 42 CFR Part 11 registration and results submission requirements.
If a designated PI leaves the institution or fails to fulfill Part 11 duties, regulatory liability snaps back to the sponsor institution.
When Does a Device Registration Record Become Public? The 11.35(b) Device Lock-Box
In drug trials, NIH publicly releases the registration record on ClinicalTrials.gov within 30 calendar days of submission (42 CFR 11.35(a)).
For medical devices, Congress created a unique commercial protection mechanism in FDAAA 801, codified in 42 CFR 11.35(b)(2):
The Unapproved Device Delayed-Posting Rule
If an Applicable Device Clinical Trial evaluates a medical device that has never previously been approved or cleared by the FDA under Section 510(k), 515, or 520(m), NIH will not publicly post the clinical trial registration record on ClinicalTrials.gov at the time of submission.
Instead, NIH holds the study record in an unreleased status (commonly known as the "Device Lock-Box") until:
- The FDA approves or clears the device product;
- Not earlier than the date of approval or clearance; and
- Not later than 30 calendar days after the date of FDA approval or clearance.
The Earlier-Posting Election & The ICMJE Trap
Under 42 CFR 11.35(b)(2)(ii), the Responsible Party may affirmatively elect to have the registration record posted publicly before FDA marketing authorization by checking the appropriate election box in the PRS portal during initial registration or at any subsequent update.
| Registration Channel / Requirement | Standard Drug Study | Unapproved Device (Default 11.35(b)(2)) | Unapproved Device (RP Elects Early Posting) |
|---|---|---|---|
| PRS Submission Deadline | Day 21 post-first enrollment | Day 21 post-first enrollment | Day 21 post-first enrollment |
| NIH Public Posting Date | Within 30 days of submission | 0–30 days after FDA approval/clearance | As soon as practicable after the election (11.35(b)(2)(ii)) |
| Competitor Visibility | Immediate (Public) | Hidden until commercial launch | Immediate (Public) |
| ICMJE Publication Eligibility | Eligible | Ineligible / High Rejection Risk | Fully Eligible |
| EU Lay Summary Compatibility | Aligned | Creates US/EU transparency gap | Aligned with global open science |
The ICMJE Compliance Trap: The International Committee of Medical Journal Editors (ICMJE) requires that all interventional clinical trials (including medical devices) be registered in a public registry at or before the time of first patient consent for enrollment as a condition of consideration for publication.
Because ICMJE accepts only publicly accessible registration, a record held in the ClinicalTrials.gov delayed-posting lockbox does not satisfy the policy: the registration exists, but it is not publicly viewable by patients, researchers, or journal editors while it is withheld. If a medical device sponsor plans to publish pivotal trial data in prestigious peer-reviewed journals (e.g., NEJM, Lancet, JAMA, Circulation), the sponsor must affirmatively elect earlier public posting under 42 CFR 11.35(b)(2)(ii) at initial registration. Relying on default delayed posting puts the manuscript at high risk of rejection for lack of public prospective registration.
When Are Results Due: The 1-Year Clock, Certificates of Delay, and Extensions
The Standard 1-Year Results Deadline (42 CFR 11.44(a))
Under 42 CFR 11.44(a), the Responsible Party must submit comprehensive clinical trial results information to the PRS not later than 1 calendar year after the study's Primary Completion Date (PCD).
- Primary Completion Date (PCD) Defined (11.10(a)): The date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome measure, whether the clinical trial concluded according to the protocol or was terminated early.
- Study Completion Date (SCD) Distinguished: The PCD is strictly tied to the primary endpoint. If a 5-year post-implantation safety follow-up continues after the 12-month primary efficacy endpoint is reached, the results clock begins ticking on the date the 12-month primary endpoint data collection is completed—not at the end of the 5-year follow-up.
Certificates of Delay: 11.44(b) vs. 11.44(c)
Recognizing that submitting proprietary clinical trial results while a marketing application is pending or before filing could compromise commercial trade secrets or patent filings, 42 CFR Part 11 provides two formal mechanisms to legally delay results submission:
+----------------------------------------------------------------------------------------------------+
| CERTIFICATE OF DELAY DECISION & TIMELINE MATRIX |
+----------------------------------------------------------------------------------------------------+
| |
| [ 42 CFR 11.44(c) - INITIAL APPROVAL ] [ 42 CFR 11.44(b) - NEW USE / APPROVED ] |
| Device NOT approved or cleared for ANY use Device ALREADY approved/cleared; studying |
| before the PCD (unapproved/uncleared product) a use not included in its labeling |
| | | |
| v v |
| [ CERTIFICATION STANDARD ] [ CERTIFICATION STANDARD ] |
| Sponsor certifies it intends to continue Sponsor certifies a marketing application |
| product development and is either seeking for the new use HAS BEEN FILED or WILL BE |
| or may at some point seek FDA approval or FILED within 1 year of the PCD |
| clearance (no filing yet required) |
| | | |
| v v |
| ================================================================================================ |
| TIMING: Certificate of Delay must be filed in PRS PRIOR to the 1-Year PCD Deadline |
| ================================================================================================ |
| | | |
| v v |
| NEW RESULTS DUE DATE: NEW RESULTS DUE DATE: |
| 30 calendar days after the EARLIER of: 30 calendar days after the EARLIEST of: |
| - FDA approves or clears the device for any - FDA approves or clears the studied use; |
| use studied in the trial; or - FDA issues a letter ending the review |
| - The application is withdrawn without cycle without approving it (e.g., a |
| resubmission for at least 210 days. Complete Response or Not Approvable); |
| - The application is withdrawn without |
| (Note: no review-cycle-letter trigger for resubmission for at least 210 days. |
| the initial-approval certificate) |
| |
| ================================================================================================ |
| STATUTORY CEILING: ABSOLUTE MAXIMUM OF 2 YEARS from the date the Certificate of Delay was filed |
| (42 CFR 11.44(b)(2) & 11.44(c)(2) - Results are due by Day 730 regardless of FDA review status) |
| ================================================================================================ |
| |
+----------------------------------------------------------------------------------------------------+
- Unapproved Device, Initial Approval (11.44(c)): Applies when the device was not approved or cleared by FDA for any use before the trial's Primary Completion Date. The Responsible Party certifies that the sponsor intends to continue product development and is either seeking, or may at a future date seek, FDA approval or clearance — no marketing application needs to have been filed yet. Results then become due 30 calendar days after the earlier of FDA approving or clearing the device for any studied use, or the application being withdrawn without resubmission for at least 210 days.
- Approved Device with New Intended Use (11.44(b)): Applies when the device is already approved or cleared, but the trial evaluates a use not in the approved labeling. The sponsor must have filed, or certify it will file within 1 year of the PCD, a marketing application for that new use. Results become due 30 calendar days after the earliest of FDA acting on that application (approval or clearance for the studied use), FDA issuing a letter that ends the review cycle without approval (such as a Complete Response or Not Approvable letter), or the application being withdrawn without resubmission for at least 210 days. A separate certification is required for each applicable trial on the same product and use (11.44(b)(3)).
- The 30-Day Trigger Window: Whichever event ends the delay, results are due within 30 calendar days of it — so an approval, a non-approval letter, or a 210-day lapse after withdrawal all start the same 30-day submission clock.
- The Hard 2-Year Statutory Ceiling: Under no circumstances can a Certificate of Delay extend results submission beyond 2 years from the date the certificate was submitted. Even if FDA review is delayed or an appeal is pending, results must be submitted on or before the 2-year anniversary.
Good-Cause Extensions (42 CFR 11.44(e))
If extraordinary circumstances prevent results submission (e.g., catastrophic data loss, ongoing blind integrity required for multi-phase cohorts, or legal injunctions), the Responsible Party may submit a formal Good-Cause Extension Request under 42 CFR 11.44(e).
The request must be filed in PRS prior to the results due date, detail the specific operational reasons why results cannot be submitted, and propose a concrete alternative deadline. The NIH Director adjudicates requests, may grant more than one extension for the same trial, and provides an electronic grant-or-deny decision with an appeal route (11.44(e)(2)–(3)); such extensions are discretionary, not guaranteed.
What Must the Results Record Contain Under 42 CFR 11.48?
Results reporting on ClinicalTrials.gov is not a narrative summary; it is a modular, structured data dataset governed by 42 CFR 11.48.
+----------------------------------------------------------------------------------------------------+
| 42 CFR 11.48 STRUCTURED RESULTS SUBMISSION MODULES |
+----------------------------------------------------------------------------------------------------+
| |
| [ MODULE 1: PARTICIPANT FLOW (11.48(a)(1)) ] |
| - Enrollment counts, arm-by-arm progression, milestones, protocol washouts |
| - Detailed subject completion, dropout counts, and specific reasons for withdrawal |
| |
| [ MODULE 2: BASELINE CHARACTERISTICS (11.48(a)(2)) ] |
| - Overall and arm-level demographics (Age, Sex/Gender, Race, Ethnicity) |
| - Study-specific baseline clinical measures (Lesion size, ejection fraction, baseline pain) |
| |
| [ MODULE 3: OUTCOME MEASURES & STATISTICAL ANALYSES (11.48(a)(3)) ] |
| - All prespecified Primary and Secondary Outcome Measures |
| - Analyzed participant denominators per arm, point estimates, dispersion (SD, SEM, 95% CI) |
| - Statistical hypothesis testing (p-values, odds ratios, hazard ratios, ANOVA/ANCOVA models) |
| |
| [ MODULE 4: ADVERSE EVENT TABLES (11.48(a)(4)) ] |
| - Table 1: All-Cause Mortality (counts and percentages by arm) |
| - Table 2: Serious Adverse Events (SAEs grouped by organ system / MedDRA SOC) |
| - Table 3: Non-Serious Adverse Events exceeding a 5% frequency within any arm |
| |
| [ MODULE 5: PROTOCOL & STATISTICAL ANALYSIS PLAN (11.48(a)(5)) ] |
| - Verbatim study Protocol and SAP uploaded as full searchable PDF documents |
| - Mandated for all clinical studies with Primary Completion Dates on or after January 18, 2017 |
| |
| [ MODULE 6: ADMINISTRATIVE & AGREEMENT DETAILS (11.48(a)(6)) ] |
| - Responsible party contact details, Data Monitoring Committee presence |
| - Disclosure of any contractual agreements restricting investigator rights to publish findings |
| |
+----------------------------------------------------------------------------------------------------+
Public Posting of Results (42 CFR 11.52)
Under 42 CFR 11.52, NIH will publicly post submitted results information on ClinicalTrials.gov not later than 30 calendar days after submission, regardless of whether the Quality Control (QC) review process has concluded.
If NIH Quality Control reviewers identify syntax errors, missing data fields, or unaddressed outcome measures, PRS issues QC review comments. Under 42 CFR 11.64(b)(1), the sponsor must correct and resubmit the results record within 25 calendar days of receiving QC comments (or within 15 calendar days for registration QC comments).
What Are the Penalties: $15,107, Form FDA 3674, and Funding Sanctions?
Violating 42 CFR Part 11 exposes medical device sponsors and principal investigators to three distinct enforcement layers:
+----------------------------------------------------------------------------------------------------+
| FDAAA 801 & 42 CFR PART 11 ENFORCEMENT ARCHITECTURE |
+----------------------------------------------------------------------------------------------------+
| |
| [ LAYER 1: GATEKEEPER - FORM FDA 3674 ] |
| - Statutory certification required with ALL 510(k), PMA, and HDE marketing applications |
| - Failure to certify or false certification = Statutory Refusal to Accept (RTA) / Refusal to File |
| - Prohibited Act under Section 301(jj)(1) of FD&C Act (21 U.S.C. 331(jj)(1)) |
| |
| [ LAYER 2: FINANCIAL - CIVIL MONEY PENALTIES (CMP) ] |
| - 21 U.S.C. 333(f)(3)(A): Single Proceeding Base Penalty = UP TO $15,107 |
| - 21 U.S.C. 333(f)(3)(B): Continuing Penalty = UP TO $15,107 PER DAY uncorrected past 30 days |
| - Adjusted annually for inflation under 45 CFR Part 102 (Effective Jan 28, 2026, 91 FR 3665) |
| |
| [ LAYER 3: ADMINISTRATIVE & FEDERAL FUNDING SANCTIONS ] |
| - FDA Notice of Noncompliance posted publicly on FDA website & flagged on ClinicalTrials.gov |
| - Per-day CMP exposure begins if not corrected within 30 days after the Notice (333(f)(3)(B)) |
| - HHS grant funding not released until compliance verified, with a 30-day cure window for |
| grantees under PHS Act 402(j)(5)(A) & 42 CFR 11.66(c) |
| - Potential federal injunctions and criminal prosecution (21 U.S.C. 333; see 42 CFR 11.66(a)) |
| |
+----------------------------------------------------------------------------------------------------+
1. Form FDA 3674: The Commercial Gatekeeper
The most immediate operational risk for medical device manufacturers is Form FDA 3674 ("Certification of Compliance with Requirements of ClinicalTrials.gov Data Bank").
Under Section 402(j)(5)(B) of the PHS Act, the certification must accompany every application or submission under sections 505, 510(k), 515, and 520(m) of the FD&C Act and section 351 of the PHS Act (per FDA's implementing guidance). For device sponsors, in practice that means every:
- 510(k) Premarket Notification;
- Premarket Approval Application (PMA) and PMA Supplement under Section 515;
- Humanitarian Device Exemption (HDE) under Section 520(m); and
- Drug and biologic counterparts (NDA under Section 505; BLA under Section 351 of the PHS Act) for combination-product teams.
On Form FDA 3674, the sponsor must certify that:
- The application does not rely on any clinical trial; OR
- The application relies on one or more clinical trials, and all applicable trials are listed with their National Clinical Trial (NCT) numbers and comply with 42 CFR Part 11.
Submitting an application without Form FDA 3674 or submitting a false certification is a prohibited act under Section 301(jj)(1) of the FD&C Act (42 CFR 11.66(a)(1)). Under FDA's Refusal to Accept (RTA) policy, CDRH document control clerks will place the marketing submission on hold before substantive technical review begins.
2. Civil Money Penalties ($15,107 Adjusted for 2026)
Under Section 303(f)(3) of the FD&C Act (21 U.S.C. 333(f)(3)) and the Federal Civil Penalties Inflation Adjustment Act, the Department of Health and Human Services (HHS) adjusts statutory penalties annually.
Pursuant to the HHS Final Rule published on January 28, 2026 (91 FR 3665, codified at 45 CFR Part 102):
- Single Proceeding Cap (21 U.S.C. 333(f)(3)(A)): Increased from $14,724 to $15,107 for all violations adjudicated in a single proceeding.
- Continuing Violation Daily Fine (21 U.S.C. 333(f)(3)(B)): Increased from $14,724 to $15,107 per day for each day the violation continues uncorrected after the expiration of the 30-day Notice of Noncompliance period.
3. Grant Funding Withholding
Under 42 CFR 11.66(c) and PHS Act Section 402(j)(5)(A), if a grantee fails to submit required registration or results data for a trial funded in whole or in part by HHS, remaining funding for that grant and funding for future grants will not be released until the required submissions are verified. The agency head first gives the grantee notice of the noncompliance and 30 days to correct it before funding is withheld.
What Has FDA Actually Enforced, and Against Whom?
While statutory penalties reach $15,107 per day, understanding how FDA exercises enforcement discretion in practice is vital for risk modeling.
According to FDA's official ClinicalTrials.gov Notices of Noncompliance and Civil Money Penalty Actions record (page content current as of February 5, 2026), the agency follows a multi-tier escalation protocol:
- Pre-Notice of Noncompliance Letter (Pre-Notice): FDA centers send a Pre-Notice requesting voluntary corrective action. FDA then conducts a further review and assessment of the ClinicalTrials.gov record and any other relevant information to determine whether a violation exists.
- Formal Notice of Noncompliance: If potential violations are not addressed after the Pre-Notice, FDA may issue a formal Notice of Noncompliance, which is posted publicly on the FDA page, and the study's ClinicalTrials.gov public record displays an "FDAAA 801 Violation" flag.
- Civil Money Penalty Action: If the responsible party does not take adequate corrective action within 30 calendar days after receiving a Notice of Noncompliance, it may be subject to civil money penalties, adjudicated under FDA CMP procedures and 21 CFR Part 17. FDA states that these violations could also result in other regulatory or enforcement actions such as injunctions or criminal prosecution.
Complete Record of FDA Notices of Noncompliance (2021–2025)
As of the page's February 2026 content date, FDA has issued eight formal Notices of Noncompliance. We independently verified each listed trial against its live ClinicalTrials.gov record in August 2026 — every one is a drug-intervention trial:
| Sponsor / Responsible Party | Date of Notice | Trial (NCT) | Intervention per CT.gov Record | Response Letter | CMP Amount |
|---|---|---|---|---|---|
| Mantia-Smaldone, Gina M., M.D. | August 4, 2025 | NCT03099499 | Drug (ONC201, endometrial cancer) | — | None |
| Mezzion Pharma Co. Ltd | March 14, 2025 | NCT03013751 | Drug (udenafil, adolescents) | Jan 28, 2026 | None |
| FADOI Foundation (Italy) | December 19, 2024 | NCT03045406 | Drug (apixaban vs. dalteparin) | Sep 30, 2025 | None |
| Light Sciences Oncology | July 19, 2023 | NCT02326454 | Drug (talaporfin sodium + device light activator) | Nov 22, 2023 | None |
| Ocugen | April 15, 2022 | NCT03785340 | Drug (brimonidine tartrate ophthalmic) | Aug 1, 2022 | None |
| Petrikovets, Andrey, M.D. | August 31, 2021 | NCT03052816 | Drug (multimodal postoperative pain regimen) | Dec 20, 2021 | None |
| Accuitis Inc. | July 26, 2021 | NCT03064438 | Drug (ACU-D1, acne rosacea) | May 26, 2022 | None |
| Acceleron Pharma, Inc. | April 27, 2021 | NCT01727336 | Drug (dalantercept + axitinib, RCC) | Dec 13, 2021 | None |
+----------------------------------------------------------------------------------------------------+
| EMPIRICAL ENFORCEMENT REALITY (2021 - 2025) |
+----------------------------------------------------------------------------------------------------+
| |
| Total Formal Notices of Noncompliance Issued by FDA: 8 |
| - Drug-Intervention Trials (verified via CT.gov records): 8 (100.0%) |
| - Medical Device Trials: 0 (0.0%) |
| |
| Total Monetary CMP Amounts Assessed (per FDA table): $0 in every case |
| - Sponsors posting a response letter on the FDA page: 7 of 8 |
| |
+----------------------------------------------------------------------------------------------------+
Key Regulatory Takeaways for Device Sponsors
- CDRH Has Never Issued a Formal Notice: Every posted notice originated from drug-program enforcement; no medical device trial has ever received a formal public Notice of Noncompliance. For devices, CDRH's practical leverage is the Form FDA 3674 gatekeeper described above.
- Zero Monetary Penalties Assessed: No civil money penalty amount has been entered in any of the eight rows. The penalty figures below are statutory authority, not observed enforcement practice.
- The Real Risk is Commercial Delay: Medical device teams that focus solely on CMP monetary risk are looking at the wrong threat. The mechanism that actually bites is Form FDA 3674: if your pivotal trial is late or missing in PRS, a false or missing certification holds up your 510(k) or PMA at acceptance review, delaying the start of substantive review and pushing commercial timelines out by months.
Live Registry Data Analysis: Device Trial Results Reporting Rates (2026)
To measure the actual extent of results disclosure compliance across the medical device sector, we analyzed live ClinicalTrials.gov API v2 data as of August 21, 2026.
To avoid skewing the analysis with newly completed studies whose 1-year statutory clock is still running, we defined a bounded cohort: completed interventional medical device studies with a Primary Completion Date on or before July 1, 2025 (at least 13 months elapsed, ensuring the standard 1-year results clock has expired).
+----------------------------------------------------------------------------------------------------+
| CLINICALTRIALS.GOV DEVICE RESULTS REPORTING ANALYSIS (AUGUST 2026) |
| (Cohort: Completed Interventional Device Trials, PCD <= July 1, 2025) |
+----------------------------------------------------------------------------------------------------+
| |
| TOTAL ELAPSED DEVICE COHORT: 30,318 Studies |
| - Studies with Results Record Submitted: 9,523 Studies (31.4%) |
| - Studies with NO Results Record: 20,795 Studies (68.6%) |
| |
| SPONSOR CLASS BREAKDOWN: |
| - Industry-Sponsored Device Trials: 9,375 Total -> 4,563 with Results (48.7%) |
| - Non-Industry (Academic/Hospital/Other): 19,720 Total -> 4,671 with Results (23.7%) |
| |
| GEOGRAPHIC & ENROLLMENT SUBSETS: |
| - U.S. Facility Location Studies: 10,433 Total -> 7,135 with Results (68.4%) |
| - Large Enrollment Studies (>= 100 Subjects): 8,563 Total -> 3,128 with Results (36.5%) |
| |
| EU MDR-ERA VOLUNTARY REGISTRATIONS: |
| - Device Interventional Trials in Germany (Started >= May 26, 2021): 614 Total (330 Industry) |
| |
+----------------------------------------------------------------------------------------------------+
Analytical Insights & Methodological Caveats
- The True Compliance Picture (68.4% in U.S.): In our earlier ClinicalTrials.gov macro-landscape analysis, we reported that only 18% of the 62,770 interventional device studies across all time had posted results. However, when filtering specifically for deadline-elapsed U.S. studies, the results-submission rate rises to 68.4%.
- Industry vs. Academic Divide: Commercial medical device manufacturers post results at more than double the rate of academic and hospital sponsors (48.7% vs. 23.7%). Commercial sponsors are bound by Form FDA 3674 and corporate legal oversight, whereas academic investigators frequently abandon registry records once primary journal manuscripts are accepted.
- Caveat on Descriptive Denominators: The 31.4% overall results rate is a descriptive registry metric, not a legal noncompliance rate. The registry denominator includes small early feasibility studies, non-significant risk studies, and foreign-only trials that registered voluntarily for journal publication but are not legally bound by 42 CFR Part 11 to post results.
What Does EU MDR Article 77 Require That ClinicalTrials.gov Does Not?
For medical device clinical investigations conducted in the European Union, EU MDR 2017/745 Article 77 (and IVDR 2017/746 Article 73 for IVDs) establishes an independent, legally binding end-of-study disclosure regime.
+----------------------------------------------------------------------------------------------------+
| EU MDR ARTICLE 77 END-OF-STUDY DISCLOSURE WORKFLOW |
+----------------------------------------------------------------------------------------------------+
| |
| [ EVENT 1: END OF CLINICAL INVESTIGATION ] |
| Last Visit of Last Subject unless the Clinical Investigation Plan sets another point (Art 77(2)) |
| | |
| +--- [ NOTIFICATION 1: Article 77(3) ] |
| | Notify EACH Member State within 15 CALENDAR DAYS of the end in that State's territory |
| | |
| +--- [ NOTIFICATION 2: Article 77(4) ] |
| | If multi-country: notify ALL Member States within 15 CALENDAR DAYS of the overall end |
| | |
| v |
| [ EVENT 2: REPORT & SUMMARY SUBMISSION (Article 77(5)) ] |
| Submit full Clinical Investigation Report (CIR) (Annex XV Section 2.8) + LAYPERSON SUMMARY |
| | |
| +--- STANDARD COMPLETION: Due within 1 CALENDAR YEAR of investigation end |
| | (scientific-reason extension possible if the CIP specifies when results are available) |
| | |
| +--- TEMPORARY HALT / EARLY TERMINATION: Due within 3 CALENDAR MONTHS |
| | |
| v |
| [ EVENT 3: PUBLIC ACCESSIBILITY IN EUDAMED (Article 77(7)) ] |
| The Clinical Investigation REPORT and Layperson Summary become public: |
| (A) When device is registered under Article 29 and before placing on market; |
| (B) IMMEDIATELY upon submission if study was terminated early or temporarily halted; OR |
| (C) At the latest 1 YEAR after entry into system if device is never registered under Article 29 |
| |
+----------------------------------------------------------------------------------------------------+
Critical EU MDR Article 77 Requirements
- 15-Day End-of-Investigation Notifications (Articles 77(3)–(4)): The sponsor must formally notify each Member State in which the investigation was conducted within 15 calendar days of the end of the investigation in that State's territory, and, for multi-country investigations, notify all concerned Member States within 15 days of the overall end across all of them. The "end" is the last visit of the last subject unless the Clinical Investigation Plan sets a different point (Article 77(2)).
- 24-Hour Safety Ground Notification (Article 77(1)): If a clinical investigation is temporarily halted or terminated early on grounds of safety (e.g., unanticipated serious adverse device effects, excess surgical morbidity), the sponsor must notify all Member States in which it is being conducted within 24 hours—far stricter than U.S. reporting clocks. (Halts or early terminations for non-safety reasons still require a 15-day notification to the affected Member State with justification, also under Article 77(1).)
- The 3-Month Early Termination Report Clock (Article 77(5)): If a trial terminates prematurely, the full Clinical Investigation Report (CIR) and lay summary must be submitted within 3 calendar months (compared to the standard 1-year clock for completed trials).
- Mandatory Layperson Summary: Article 77(5) and Annex XV Section 2.8 mandate that the CIR must be accompanied by a summary written in terms understandable to the intended user (layperson summary), fulfilling the ethical promise made in the subject's Article 63 informed consent form.
- Public Accessibility Rules (Article 77(7)): The clinical investigation report itself and the lay summary are both publicly released in EUDAMED:
- At the latest when the device is registered under Article 29 (UDI registration) and before market placement;
- Immediately upon submission if the investigation was terminated early or halted;
- No later than 1 year after system entry if the device is never registered or commercialized.
Do EU Device Trials Go Into CTIS, EUDAMED, or ClinicalTrials.gov?
Clinical operations teams managing European device trials frequently struggle with registry routing.
+----------------------------------------------------------------------------------------------------+
| EUROPEAN DEVICE TRIAL REGISTRY ROUTING MATRIX (2026) |
+----------------------------------------------------------------------------------------------------+
| |
| [ REGISTRY 1: CTIS (Clinical Trial Information System) ] |
| - Governed by Regulation (EU) No 536/2014 (Clinical Trials Regulation - CTR) |
| - SCOPE: EXCLUSIVELY MEDICINAL PRODUCTS (DRUGS & BIOLOGICS) |
| - RULE FOR DEVICES: DEVICE-ONLY CLINICAL INVESTIGATIONS CANNOT BE ENTERED IN CTIS |
| - EXCEPTION: Combination product trials where the primary active substance is a medicinal product |
| |
| [ REGISTRY 2: EUDAMED (European Database on Medical Devices) ] |
| - Governed by EU MDR 2017/745 Article 33 & Article 77 |
| - 2026 STATUS: 4 Modules mandatory as of May 28, 2026 (Commission Decision (EU) 2025/2371) |
| - CI/PS MODULE STATUS: Clinical Investigation & Performance Studies module is UNDER DEVELOPMENT |
| - OPERATIONAL CHANNEL IN 2026: Submissions run via NATIONAL COMPETENT AUTHORITY PORTALS |
| (e.g., BfArM DMIDS in Germany, ANSM in France, AEMPS in Spain, FAMHP in Belgium) |
| |
| [ REGISTRY 3: ClinicalTrials.gov (U.S. PRS) ] |
| - Governed by U.S. 42 CFR Part 11 |
| - STATUS FOR EU TRIALS: VOLUNTARY (Unless trial has a U.S. site, IDE number, or U.S. export) |
| - PRACTICE: EU device trials land here only by election or ADCT trigger — e.g., 614 |
| interventional device trials with German sites started in the MDR era (330 industry-led) |
| |
+----------------------------------------------------------------------------------------------------+
Why CTIS Excludes Medical Devices
Under Articles 1 and 2(1) of Regulation (EU) No 536/2014, CTIS is legally established solely for clinical trials of medicinal products for human use. Device-only investigations conducted under MDR Article 62 or IVDR Article 58 are legally outside the CTR scope and cannot be registered in CTIS.
The 2026 EUDAMED Operational Status
Under European Commission Decision (EU) 2025/2371 (adopted November 26, 2025, published in the OJEU on November 27, 2025), four EUDAMED modules became mandatory on May 28, 2026:
- Actor Registration;
- UDI and Device Registration;
- Notified Bodies and Certificates; and
- Market Surveillance.
However, the Clinical Investigations and Performance Studies (CI/PS) module remains in technical development, with no voluntary-use period planned prior to full mandatory release.
Consequently, in 2026, European device trial sponsors must submit Article 77 end-of-study notifications, CIRs, and layperson summaries through national competent authority portals (such as the German DMIDS, French ANSM, or Spanish AEMPS systems) following Member State transitional rules.
US 42 CFR Part 11 vs. EU MDR Article 77 vs. IVDR Article 73
| Regulatory Parameter | U.S. 42 CFR Part 11 / FDAAA 801 | EU MDR 2017/745 Article 77 | EU IVDR 2017/746 Article 73 |
|---|---|---|---|
| Governing Legislation | PHS Act 402(j), FD&C Act 301(jj), 42 CFR 11 | Regulation (EU) 2017/745, Article 77 | Regulation (EU) 2017/746, Article 73 |
| Applicable Scope | Applicable Device Clinical Trials (ADCTs) | All clinical investigations under Art 62 / 74(1) | All performance studies under Art 58 / 70(1) |
| Initial Registration Due Date | Within 21 calendar days of first enrollment | Prior to study start (CIV-ID / Single ID) | Prior to study start (CIV-ID / Single ID) |
| Public Registry Name | ClinicalTrials.gov (PRS) | EUDAMED CI Module (National portals in 2026) | EUDAMED PS Module (National portals in 2026) |
| Unapproved Product Delayed Posting | Held in "Device Lock-Box" until FDA approval | CIR summary public upon Art 29 registration | Report summary public upon Art 26 registration |
| Study End Notification Clock | 30 days update for Study Completion Date | 15 calendar days to all concerned MS | 15 calendar days to all concerned MS |
| Safety Halt Notification Clock | Standard SAE clocks (10 days / 30 days) | Within 24 hours to all concerned MS | Within 24 hours to all concerned MS |
| Results / Report Due Date | 1 calendar year post-PCD (11.44(a)) | 1 calendar year post-investigation end | 1 calendar year post-study end |
| Early Termination Report Clock | Standard 1-year clock (PCD updated) | 3 calendar months (Art 77(5)) | 3 calendar months (Art 73(5)) |
| Delay / Extension Mechanisms | Certificate of Delay (11.44(b)/(c), 2-yr max) | Justified in CIP for scientific reasons | Justified in CPSP for scientific reasons |
| Layperson Summary Required? | Optional / Not mandated in Part 11 | Mandatory under Article 77(5) | Mandatory under Article 73(5) |
| Marketing Submission Gatekeeper | Form FDA 3674 attached to 510(k)/PMA | Technical Documentation Annex II / III audit | Technical Documentation Annex II / III audit |
| Maximum Statutory Fine | $15,107 / day (2026 HHS adjustment) | National penalties under Member State law | National penalties under Member State law |
The Unified Dual-Jurisdiction Disclosure Calendar
For sponsors running a pivotal medical device investigation across both U.S. and European clinical sites, managing separate compliance calendars is an invitation to regulatory default. Clinical operations teams must implement a single, unified disclosure calendar:
+----------------------------------------------------------------------------------------------------+
| UNIFIED US / EU DEVICE TRIAL DISCLOSURE CALENDAR |
+----------------------------------------------------------------------------------------------------+
| |
| [ MILESTONE 1: FIRST PATIENT IN (FPI) ] |
| - U.S. Clock: Register on ClinicalTrials.gov within 21 CALENDAR DAYS (42 CFR 11.24(a)) |
| - Action: Decide ICMJE public election vs. 11.35(b) Device Lock-Box in PRS |
| |
| [ MILESTONE 2: TRIAL CONDUCT & ANNUAL MAINTENANCE ] |
| - U.S. Clock: Update PRS record at least ONCE EVERY 12 MONTHS (42 CFR 11.64(a)) |
| - U.S. Clock: Update Recruitment Status / Site Changes within 30 CALENDAR DAYS (11.64(a)(1)(ii)) |
| |
| [ MILESTONE 3: PRIMARY COMPLETION DATE (PCD reached) ] |
| - U.S. Clock: Update actual PCD in PRS within 30 CALENDAR DAYS (11.64(a)(1)(ii)(I)) |
| - U.S. Clock: 1-Year Results Clock Starts Ticking (42 CFR 11.44(a)) |
| |
| [ MILESTONE 4: LAST PATIENT OUT (LPO) / END OF INVESTIGATION ] |
| - EU Clock: Notify concerned EU Member States within 15 CALENDAR DAYS (MDR Art 77(3)-(4)) |
| - EU Clock: 1-Year Clinical Investigation Report (CIR) Clock Starts Ticking (Art 77(5)) |
| - Safety Exception: If halted for safety, notify ALL Member States WITHIN 24 HOURS (Art 77(1)) |
| |
| [ MILESTONE 5: MARKETING APPLICATION SUBMISSION (510(k) / PMA) ] |
| - U.S. Gatekeeper: File FORM FDA 3674 listing NCT number and certifying Part 11 compliance |
| - U.S. Action: Submit Certificate of Delay under 11.44(c) if filing before 1-Year Results Due Date |
| |
| [ MILESTONE 6: 1 YEAR POST-PCD / STUDY END ] |
| - U.S. Clock: Submit full structured Results + SAP/PDF to PRS (Unless valid Delay filed) |
| - EU Clock: Submit CIR + Validated Layperson Summary to National Portals (MDR Art 77(5)) |
| - Early Termination Note: If study terminated early, EU CIR was due at MONTH 3 |
| |
| [ MILESTONE 7: FDA APPROVAL / CE MARKING / ARTICLE 29 REGISTRATION ] |
| - U.S. Clock: Submit results within 30 DAYS of FDA action if Certificate of Delay was active |
| - U.S. Clock: NIH releases Lock-Box registration record within 30 DAYS of approval (11.35(b)) |
| - EU Clock: CIR Summary & Lay Summary become public in EUDAMED upon Article 29 registration |
| |
+----------------------------------------------------------------------------------------------------+
Sponsor Operational Playbook: 6 Compliance Failure Modes & SOP Controls
1. The "Foreign Sites Only" IDE Blindspot
- The Failure: Sponsor runs a pivotal trial under a U.S. IDE exclusively at European and Canadian surgical centers. The team assumes that because no U.S. patients are enrolled, ClinicalTrials.gov registration is unnecessary.
- The Consequence: The trial is an ADCT under 42 CFR 11.22(b)(1)(ii)(D)(3). When the PMA is submitted, Form FDA 3674 reveals an unregistered applicable trial, triggering a Refusal to File (RTF) and halting PMA review.
- SOP Control: Any protocol bearing an FDA IDE number must be flagged automatically in the regulatory management system as a mandatory 21-day PRS registration deliverable.
2. The ICMJE Lock-Box Desk-Rejection
- The Failure: Sponsor registers an unapproved implantable device within 21 days but relies on default delayed posting under 42 CFR 11.35(b)(2). The clinical steering committee submits the pivotal 12-month data to a major journal (NEJM / Lancet), which immediately desk-rejects the manuscript for lack of public prospective registration.
- The Consequence: Permanent loss of top-tier medical journal publication; commercial launch is delayed because key opinion leaders cannot cite published pivotal data.
- SOP Control: At initial protocol drafting, the steering committee must decide whether journal publication is required. If yes, the PRS record must be submitted with the earlier-posting election box checked.
3. The PCD vs. Study Completion Date Confusion
- The Failure: A trial has a 12-month primary efficacy endpoint (PCD) and a 5-year long-term safety follow-up. The sponsor plans to submit results 1 year after the 5-year follow-up ends.
- The Consequence: The 42 CFR Part 11 results clock is anchored strictly to the Primary Completion Date (11.10(a)). The sponsor is 4 years delinquent, receives an FDA Pre-Notice Letter, and faces an "FDAAA 801 Violation" flag on ClinicalTrials.gov.
- SOP Control: Calendar results submission exactly 365 calendar days post-PCD, regardless of ongoing long-term safety cohorts.
4. The Missed Certificate of Delay Deadline
- The Failure: A device sponsor intends to file a Certificate of Delay under 42 CFR 11.44(c) while its PMA is under review, but forgets to submit the certificate in PRS before the 1-year PCD anniversary.
- The Consequence: Once the 1-year deadline passes, PRS locks out delay certifications. The trial is immediately categorized as noncompliant, and the sponsor cannot retroactively delay results.
- SOP Control: Set automated calendar triggers at 90, 60, and 30 calendar days before the 1-year PCD deadline to ensure Certificates of Delay are filed before the clock runs out.
5. The EU 3-Month Early Termination Cliff
- The Failure: A European clinical investigation is terminated early due to poor recruitment. The sponsor assumes the Clinical Investigation Report is due in 1 year, as in standard completion.
- The Consequence: Under MDR Article 77(5), early termination shortens the CIR submission deadline from 12 months to 3 calendar months. The sponsor misses national portal deadlines, triggering competent authority noncompliance notices.
- SOP Control: In the trial closure SOP, embed an automated branch: if study termination is premature, set CIR and layperson summary drafting deliverables to 60 calendar days post-halt to ensure filing within 3 months.
6. The Missing Layperson Summary
- The Failure: Sponsor prepares a rigorous, technical 200-page Clinical Investigation Report under Annex XV Section 2.8 but omits the layperson summary.
- The Consequence: National competent authorities reject the Article 77 submission package as incomplete, violating MDR Article 77(5) and Article 63(6).
- SOP Control: Commission a validated, readability-tested layperson summary (Grade 6–8 reading level) concurrently with the technical CIR.
Frequently Asked Questions (FAQs)
Do early feasibility studies (EFS) have to be registered on ClinicalTrials.gov?
Under 42 CFR 11.10(a) and 42 CFR 11.22(b)(1)(ii)(B), small feasibility studies and prototype evaluations designed primarily to test product feasibility or refine design are not Applicable Device Clinical Trials and are not legally required to register under 42 CFR Part 11. However, if the sponsor intends to publish study results in an ICMJE-member medical journal, the study must be registered voluntarily prior to enrolling the first patient.
Is a device trial with only non-U.S. sites still an applicable device clinical trial?
Yes, if it meets any of the other jurisdictional triggers under 42 CFR 11.22(b)(1)(ii)(D). Specifically, if the trial is conducted under an FDA IDE number or if the investigational device was manufactured in and exported from the United States, the study is legally an ADCT subject to mandatory registration and results reporting regardless of site geography.
Can we delay posting results until our PMA is approved?
Yes, provided your device was not approved or cleared for any use before the trial's Primary Completion Date and you submit a formal Certificate of Delay under 42 CFR 11.44(c) through the PRS portal prior to the 1-year primary completion deadline. This moves your results submission deadline to 30 calendar days after the earlier of FDA approval or clearance for a studied use, or withdrawal of the application without resubmission for at least 210 days, subject to an absolute statutory cap of 2 years from the date the Certificate of Delay was submitted.
What happens if we registered our clinical trial late?
Registering past the 21-day deadline is a statutory violation of 42 CFR 11.24(a). You must register immediately through PRS. ClinicalTrials.gov will automatically display the date of first enrollment alongside the registration submission date, making late registration publicly visible. Late registration may also trigger ICMJE publication rejections, but completing registration cures the statutory block for Form FDA 3674 marketing application clearance.
Has FDA ever issued a civil money penalty against a medical device sponsor?
No. As of February 2026, FDA has issued eight formal Notices of Noncompliance (all against pharmaceutical and biologic trials), and CDRH has never issued a formal public notice or assessed a monetary fine against a medical device sponsor. In practice, CDRH enforces compliance through informal Pre-Notice letters and by enforcing Form FDA 3674, which blocks 510(k) and PMA acceptance if registration or results requirements are violated.
Does a Section 522 postmarket surveillance study have to post results?
Yes. Under 42 CFR 11.10(a) and 42 CFR 11.22(b)(1)(i), any pediatric postmarket surveillance study of a medical device ordered by FDA under Section 522 of the FD&C Act is explicitly defined as an Applicable Device Clinical Trial. The ordered entity must register the study within 21 days and submit results within 1 year of completion.
Does the EU layperson summary become public even if the device is never approved?
Yes. Under EU MDR Article 77(7), if a clinical investigation is terminated early or temporarily halted, the clinical investigation report and the layperson summary become publicly accessible immediately upon submission. If the study completes normally but the device is never registered or placed on the market, the report and summary become publicly accessible in EUDAMED no later than 1 year after entry into the system.
Further Reading & Related Clinical Evidence Guides
- ClinicalTrials.gov Medical Device Database Analysis: 2026 Landscape
- Safety Reporting in Medical Device Clinical Trials: 21 CFR 812 & EU MDR Article 80
- Informed Consent for Medical Device Clinical Trials: 21 CFR 50 & EU MDR Article 63
- EU MDR Clinical Investigation Sponsor Obligations & Timelines Guide
- Medical Device Clinical Trial Termination Reasons & Operational Analysis
- FDA Section 522 Postmarket Surveillance Studies Guide
- FDA Early Feasibility Studies (EFS) for Medical Devices Guide
- Medical Device Investigational Device Exemption (IDE) Guide
- Diversity Action Plans (DAP) for Medical Device Clinical Trials: FDORA Guide
- Good Clinical Practice (GCP) for Medical Device Clinical Trials
- ISO 14155:2026 Medical Device Clinical Investigations Standard Guide
- Data Monitoring Committees (DMC / DSMB) for Medical Device Trials
- Protocol Deviations Management in Medical Device Clinical Trials
- Risk-Based Monitoring (RBM) for Medical Device Clinical Trials